Funded Startups in Massachusetts
Massachusetts deal sizes show a clear head: Commonwealth Fusion raised $1.0B on 2026-07-30, and it sits far above the next disclosed rounds, with Phoenix T…
Massachusetts deal sizes show a clear head: Commonwealth Fusion raised $1.0B on 2026-07-30, and it sits far above the next disclosed rounds, with Phoenix Tailings at $500M (2026-06-16) and Dyne Therapeutics at $200M (2026-06-17). Beyond the top of the distribution, the list is heavily concentrated in mid-to-larger disclosures, with 6 disclosed rounds at or above $100M (including Beeline Medicines at $126M on 2026-06-30 and Scaled Cognition at $100M on 2026-06-25) and 12 at or above $50M.
Geographically, the entries cluster around Boston: Boston accounts for 16 of the 50 rows, including multiple high-disclosure companies such as Beeline Medicines ($126M, 2026-06-30) and Flare Therapeutics is Cambridge-based instead, while Cambridge has 15 rows with the $1.0B Commonwealth Fusion and LifeMine Therapeutics at $188M on 2026-08-06. Temporally, the displayed rounds span 2026-06-11 to 2026-08-06, with 2026 contributing all 50 rows, and 8 of 50 rounds reporting undisclosed amounts.
Most recent rounds
50 of 1,8101,760 more funded startups
This page shows the 50 most recent rounds (back to Jun 2026). The full 1,810-company history for this listing is available on a paid plan.
Unlock all 1,810 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which single disclosed round is the outlier in Massachusetts, and what are the next closest disclosed amounts?
Commonwealth Fusion’s $1.0B round (2026-07-30, Cambridge) is the only disclosed deal above $1.0B, dwarfing Phoenix Tailings’ $500M (2026-06-16, Woburn) and Dyne Therapeutics’ $200M (2026-06-17, Cambridge).
How concentrated are round sizes at the high end based on disclosed amounts?
Disclosed amounts reach the $100M threshold in 6 rounds (e.g., Beeline Medicines at $126M on 2026-06-30; Scaled Cognition at $100M on 2026-06-25), while 12 rounds are at or above $50M (including LifeMine Therapeutics at $188M on 2026-08-06 and Hyperlight at $80M on 2026-06-18).
Do cities cluster around a single hub, or is the spread across Massachusetts?
Boston is the most represented city with 16 rows, including Dash Bio ($30M, 2026-08-03), Beeline Medicines ($126M, 2026-06-30), and SOPHiA GENETICS ($58M, 2026-06-16). Cambridge is close behind with 15 rows, including LifeMine Therapeutics ($188M, 2026-08-06) and Commonwealth Fusion ($1.0B, 2026-07-30).
What stage labels show the most volume in this Massachusetts snapshot?
Series Unknown dominates at 25 of 50 entries, followed by Series A at 8 and Seed at 7; other stages appear less frequently (Series C: 5, Series B: 2, plus one each for Series E, Private Equity, and Pre-Seed).
Which sectors repeat most often, and how much of the list stays at the higher-disclosure levels?
Biotechnology (19) and AI (8) are the most frequent repeated sectors (both appear more than once), alongside Health Care (7). At the high-disclosure tiers, the list includes multiple sector leaders such as Biotechnology’s LifeMine Therapeutics at $188M (2026-08-06) and AI’s none among the top 8 disclosed amounts (top 8 are led by Commonwealth Fusion, Phoenix Tailings, Dyne Therapeutics, LifeMine Therapeutics, Beeline Medicines, Scaled Cognition, Flare Therapeutics, and Hyperlight).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.